AMGN vs NAMS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

AMGN is the larger of the two ($237.84B market cap): the incumbent the market prices for continued execution (17.53x forward earnings, beta 0.42). NAMS is the smaller challenger ($2.27B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, NAMS fits: analysts expect its revenue to rise 21% next year, against 5% for AMGN. If you believe in profit, AMGN fits: it is expected to make money next year (17.53x forward earnings), while NAMS is still expected to post a loss.

AMGN vs NAMS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricAMGNNAMSWhat it tells you
Market cap$237.84B$2.27BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E17.53-9.13Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.420.14Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range74% of range4% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book16.573.60How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how AMGN and NAMS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and NAMS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and NAMS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Amgen (AMGN) do?

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Full AMGN guide

What does NewAmsterdam Pharma Company (NAMS) do?

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company headquartered in Naarden, the Netherlands, and listed on Nasdaq under the ticker NAMS. Its lead candidate is obicetrapib, an oral, once-daily, low-dose CETP inhibitor being developed as a non-statin option (alone or as a fixed-dose combination with ezetimibe) to lower LDL cholesterol in patients who are not reaching targets on existing therapy. The company reported positive topline data from registrational Phase 3 trials including BROADWAY, BROOKLYN and TANDEM, and is running the large PREVAIL cardiovascular outcomes trial; European rights are partnered with the Menarini Group, and on September 21, 2026 the European Commission approved obicetrapib as Ubeslo (10 mg monotherapy) and Evlarco (with 10 mg ezetimibe) for primary hypercholesterolaemia, the drug's first approval worldwide. A Phase 2b trial called SPINOZA, which dosed its first participant in September 2026, now tests obicetrapib in preclinical Alzheimer's disease, building on an earlier Phase 2a program.

Full NAMS guide

AMGN vs NAMS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
  • NAMS drivers: Obicetrapib approval path; Oral, once-daily convenience versus injectables.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For NAMS, the company is still essentially pre-revenue, with about $26 million of trailing revenue, much of it one-time Menarini milestones, against a trailing net loss of about $205 million, so the valuation depends on obicetrapib being approved in the US and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis.

AMGN or NAMS: which should you pick?

If the story you believe is AMGN's (Rare disease and Horizon assets), AMGN is the more direct way to own it; if it is NAMS's (Obicetrapib approval path), NAMS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMGN and NAMS guides.

AMGN vs NAMS: the full fundamentals

AMGN. As of November 20, 2026, Amgen trades at about 25x trailing GAAP earnings and about 17.5x forward earnings, with EV/EBITDA near 16x, a higher multiple than early 2026 after the shares gained about a third. The dividend yield is about 2.3%. The next report is expected around February 2, 2027, with consensus for the December quarter of adjusted EPS near $5.61 on about $10.48 billion of revenue; the 29 analysts covering the stock rate it a Hold on average, with a mean target of about $436, close to the current price.

NAMS. The revenue base is small and lumpy, consisting mainly of milestone and supply income under the Menarini agreement, so traditional multiples are not meaningful. At about $2.3 billion, the market cap is roughly 3.5 times the cash balance, down from about $4.4 billion in May, as the EU approval was overshadowed by doubts about the PREVAIL interim. Analysts expect about $34.6 million of revenue in 2026 and $42.0 million in 2027, with losses continuing, and 14 analysts carry a mean target near $51.

Headline figures (approximate, November 2026): AMGN shows revenue (ttm) ~$38.9 billion, revenue growth (q3 2026, yoy) ~8.5%, operating margin ~34%, net income (ttm) ~$9.4 billion; NAMS shows revenue (ttm) ~$26M; Q3 2026 ~$19.2M, mostly Menarini milestones, net loss (ttm) ~$205M; Q3 2026 ~$17.4M (incl. ~$23.1M warrant gain), eps (q3 2026) ~-$0.12 vs ~-$0.44 expected, cash ~$643M cash and securities, negligible debt.

The bottom line: AMGN vs NAMS

AMGN and NAMS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AMGN and NAMS exposure against your real portfolio. It is not an investment adviser.

Wondering how AMGN or NAMS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Amgen

Ask Walnut's AI anything about AMGN and see how it fits what you own.

FAQ

What is the difference between AMGN and NAMS?

+

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. NewAmsterdam Pharma Company N.V. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is AMGN or NAMS the better stock?

+

Neither is universally better. AMGN is the larger incumbent; NAMS is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, AMGN or NAMS?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both AMGN and NAMS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of AMGN vs NAMS?

+

AMGN: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including MariTide and its other obesity programs, can fail in late-stage trials or face regulatory setbacks. Newer franchises face their own competition, such as Viridian's Lumvoa against Tepezza. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition left Amgen with about $54 billion of total debt against about $13 billion of cash as of September 30, 2026. After a 34% year-to-date gain the share price of about $440 sits near the ~$436 average analyst target (Mizuho's target is $388 with a Neutral rating), and consensus expects about 8% EPS growth in 2026 and 6.5% in 2027, so the valuation already assumes steady execution. Litigation, manufacturing, and safety risks are inherent to the industry. NAMS: The company is still essentially pre-revenue, with about $26 million of trailing revenue, much of it one-time Menarini milestones, against a trailing net loss of about $205 million, so the valuation depends on obicetrapib being approved in the US and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. The near-term risk is sharper now: RBC's statistical work puts the chance of a positive PREVAIL interim in early 2027 at 35% to 38%, and an interim that falls short would at minimum push the outcomes story out to the final analysis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion of about $643 million. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles, and the stock's roughly 46% drop in 2026 shows how quickly sentiment can move. Third-quarter revenue also flattered the run rate: analysts expect only about $1.2 million of revenue in the first quarter of 2027 once milestone payments fall away, and the narrower Q3 loss leaned on a non-cash warrant gain.

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AMGN or NAMS; figures are approximate and dated (as of November 2026). Verify current data before investing.